Vivimed Labs Ltd is hoping to cash in on the global market potential for formulations post its acquisition of Spain-based active pharmaceutical ingredients maker, Uquifa, early this month. The Hyderabad-based company would go for backward integration by shifting Uquifa's pharma ingredients production to India.
Another plant to make finished dosages is also being set up exclusively for regulated markets at Choutuppal near here. “The combined investment in these plants is about Rs 190 crore. All of them should begin production by end of next financial year. The pharma business was moving towards finished dosages for sustainable growth.
The turnover of the company would zoom to Rs 1,000 crore by end of next financial year with an equal share of specialty chemicals and pharmaceuticals in revenue. The operations of Uquifa which are now in the UK and Spain would be rationalised by bringing everything to Spain.
